| answer text |
<p>The Government has decided not to procure Evusheld for prevention through emergency
routes at this time. This is a decision based on independent clinical advice by the
multi-agency initiative, RAPID C-19 and a national expert policy working group. These
groups considered a range of evidence, including clinical trial data, in vitro analysis
and emerging observational studies and concluded there is currently insufficient evidence
of benefit to recommend deployment. The Chief Medical Officer for England is content
that the correct process for providing clinical advice has been followed and agree
that this should now be referred to the National Institute for Health and Care Excellence
for further evaluation.</p><p>The Department wrote to patient groups on 5 September
2022 with information on this decision and evidence considered. The letter summarised
the evidence considered by RAPID C-19 which contributed to the decision not to procure
and deploy Evusheld and detailed the next steps the Government will take. The Department
intends to publish further details of the clinical advice received shortly.</p>
|
|
